Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12162855

    Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12161706

    Cancer vaccines targeting BORIS and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12161607

    Combination of cannabinoids in the treatment of leukemia

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12162870

    Anticancer compounds

    The Regents of the University of California · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12162950

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    JANUX THERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12146139

    Oligonucleotide interference treatments of prostate cancer

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12144809

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12139764

    Systems and methods for characterizing and treating breast cancer

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12134650

    Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12121288

    Combination tumor treatment

    Regents of the University of Minnesota · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12122846

    Chimeric antigen receptor for tumor targeting

    Fate Therapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12116637

    Compositions and methods for detecting and treating high grade subtypes of uterine cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12116375

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12109224

    USB1 directed regulation of miRNAs related hematopoietic differentiation and affected in multiple forms of leukemia

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12109225

    Methods for potentiating cancer treatment using ionizing radiation

    GLYCOMIRA THERAPEUTICS, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12104172

    Processes for generating TIL products enriched for tumor antigen-specific t-cells

    Iovance Biotherapeutics, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12103960

    VEGF traps and mini-traps and methods for treating ocular disorders and cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12103978

    Methods and materials for treating cancer

    SHANGHAI MIRACOGEN INC. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12097198

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12098138

    Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases

    The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12097213

    Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12090142

    Combination therapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12090183

    Methods of treating solid or lymphatic tumors by combination therapy

    CG ONCOLOGY, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12083113

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12076324

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12077507

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12077760

    DNA aptamers and use thereof for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12076409

    Polymer-drug conjugates for combination anticancer therapy

    The Regents of the University of California · Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12070443

    Methods of treating and preventing breast cancer with S-equol

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Montefiore Medical Center · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12070500

    Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

    VACCINEX, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12064413

    Methods of treating melanoma with S-equol

    The Board of Regents of the University of Texas System · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12064473

    Cancer vaccines targeting Survivin and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12064507

    Composition and method for oral treatment of leukemia

    Provectus Pharmatech, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12059443

    Method for treating cancer using dengue virus serotype 1 (DENV-1)

    PrimeVax Immuno-Oncology · Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.